Assessment of monocytic‐myeloid‐derived suppressive cells (M‐MDSC) before and after allogeneic hematopoietic stem cell transplantation in acute leukemia patients
Open Access
Abstract
In this monocentric prospective study, the influence on long‐term outcomes of peripheral blood levels of monocytic‐myeloid‐derived suppressive cells (M‐MDSC) was investigated in 56 patients with acute leukemia (myeloid n = 47; lymphoid n = 9) before and after (Days+60/+90) allogeneic hematopoietic stem cell transplantation (Allo‐HSCT). A risk of relapse was found to be associated with a level of pregraft M‐MDSC above 1.4% by ROC curve analysis. In multivariate analysis, this threshold retained a strong statistical significance (HR: 5.94 [2.09–16.87], p = 0.001). Considering only the group of patients who were in complete remission prior to Allo‐HSCT (n = 44), a significant prediction of relapse was found to be associated, in multivariate analysis, with a level of pregraft M‐MDSC above 1.4% (HR: 55.01 [14.95–202.37], p < 0.001) together with pregraft‐positive measurable ‐residual disease (MRD) (HR: 11.04 [1.89–64.67], p = 0.008). A poorer OS (HR: 6.05 [1.24–29.59], p = 0.026) and disease‐free survival (HR: 6.52 [1.41–30.19], p = 0.016) were also associated with higher levels of pregraft M‐MDSC. Remarkably, no relapse occurred in patients with pregraft‐negative MRD and ≤1.4% of M‐MDSC (vs. a 3‐year relapse rate of 60% for others, p = 0.004). Patients developing grade 3–4 acute graft‐versus‐host‐disease (GVHD, median occurrence: day+30 posttransplant) showed significantly higher levels of M‐MDSC% at days +60 and +90, suggesting a possible amplification of these immunosuppressive cells as a reaction to GVHD. In conclusion, this prospective study demonstrates a negative impact of higher proportions of peripheral M‐MDSC before Allo‐HSCT in leukemic patients. This paves the way to potential therapeutic intervention to decrease M‐MDSC levels before Allo‐HSCT and thus perhaps the incidence of relapse in such patients.Keywords
This publication has 21 references indexed in Scilit:
- Predictive Role of Circulating Immune Cell Subtypes Early after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute LeukemiaInternational Journal of Stem Cells, 2019
- Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)Bone Marrow Transplantation, 2018
- Matrix Metalloproteinase-9 in Monocytic Myeloid-Derived Suppressor Cells Correlate with Early Infections and Clinical Outcomes in Allogeneic Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2018
- Recommendations for myeloid-derived suppressor cell nomenclature and characterization standardsNature Communications, 2016
- Circulating CD14+HLA‐DR‐/low myeloid‐derived suppressor cells in leukemia patients with allogeneic hematopoietic stem cell transplantation: novel clinical potential strategies for the prevention and cellular therapy of graft‐versus‐host diseaseCancer Medicine, 2016
- Functional Myeloid-Derived Suppressor Cell Subsets Recover Rapidly after Allogeneic Hematopoietic Stem/Progenitor Cell TransplantationTransplantation and Cellular Therapy, 2015
- Monocytic and promyelocytic myeloid‐derived suppressor cells may contribute to G‐CSF‐induced immune tolerance in haplo‐identical allogeneic hematopoietic stem cell transplantationAmerican Journal of Hematology, 2014
- History of myeloid-derived suppressor cellsNature Reviews Cancer, 2013
- Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantationLeukemia, 2012
- Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1–dependent mechanism that is up-regulated by interleukin-13Blood, 2010